Looks quite reasonable $NWRN:
+ EV / Sales (5.29)
+ Gross Margin TTM (98.26%)
+ Rule-of-40 Score TTM (432.88%)
+ Sales Growth TTM (467.18%)
+ PEG TTM (0.04)
+ Return on equity LJ (1086.63%)
+ EBIT margin LJ (50.93%)
- Debt ratio (34.68)
- Equity ratio LJ (2.28%) ✌🏻
+ EV / Sales (5.29)
+ Gross Margin TTM (98.26%)
+ Rule-of-40 Score TTM (432.88%)
+ Sales Growth TTM (467.18%)
+ PEG TTM (0.04)
+ Return on equity LJ (1086.63%)
+ EBIT margin LJ (50.93%)
- Debt ratio (34.68)
- Equity ratio LJ (2.28%) ✌🏻
•
22
•
@PiHu I'm registered at https://aktien.guide/ (premium account) I think the site is really great and very clear ✌🏻
•
33
•
@Anderle There is always the risk that Evenamide will not be approved and then the price will plummet.
•
22
•@Sam_Mumm Correct, the risk exists for all pharmaceutical and biotechnology companies.
•
33
•@Sam_Mumm if everything goes well, is it possible to say when the approval will come? @
••
@FB2plus2is4 Q4 2026 is expected, but I would prefer a takeover before then. I recently lost a lot of money on Anavex, as the expected approval did not come.
•
11
•••
@FB2plus2is4 There is a big risk with all biotechs, but with Newron I am very sure that we are heading towards CHF 100 the closer we get to approval. The studies are very well prepared, there is even an extra phase II study in the USA. However, I expect a takeover before approval.
•
11
•@Sam_Mumm What exactly would such a takeover mean? I have only recently joined the company. Thanks for the explanation...
••
@FB2plus2is4 There are only 22 million shares, and if you offset the share price against this, the MK is still far too low. If we take the two license deals for Japan and South Korea as a basis, we arrive at a market capitalization of around 1.4 billion euros. Further forecasts are difficult, but if you observe the share price and order book, you can come to the conclusion that someone is collecting on a large scale and preparing a takeover. I don't dare to predict at what price. But there is a current valuation of CHF 73. We'll see 🙂
•
11
•